References
1. C.S Goodman, "HTA 101: Introduction to Health Technology Assessment" (National Information Center on Health Services Research
and Healthcare Technology, US National Library of Medicine, National Institutes of Health, January, 2004),
http://www.nlm.nih.gov/, accessed 12 August 2011.
2. H. Redwood, Why Ration Health Care? (CIVITAS, London, UK 2000).
3. Charles River Associates, A Comparative Analysis Of The Role And Impact Of Health Technology Assessment (2011, MA, USA).
4. C. Sorenson, M. Drummond and P. Kanavos, The Role Of Health Technology Assessment In The European Union. The European Observatory on Health Systems and Policies (MPG Books, Cornwall, UK, 2008).
5. Tufts Center for the Study of Drug Development, "Drug Developers Are Aggressively Changing the Way They Do R&D", Press Release
(MA, USA, 2011).
6. K. Grogan, "Uproar over NICE rejection of Novartis MS pill", Pharma Times (5 August 2011).
7. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), "The German IQWiG — It's Not NICE Benefit Assessment
in Germany — New Sense or Nuisance?"
http://www.ispor.org/, accessed 8 August 2011.
8. International Network of Agencies for Health Technology Assessment (INAHTA), "IQWIG — Institut für Qualität und Wirtschaftlichkeit
im Gesundheitswesen"
http://www.inahta.org/, accessed 8 August 2011.
9. A. Jouan, Le Figaro (27 March 2011).
http://www.lefigaro.fr/, accessed 12 August 2011.
10. Haute Autorité de Santé, "Le NICE, l'IQWIG et la HAS concluent un accord de coopération", Press Release, (France, 13 April
2006).
11. Haute Autorité de Santé, "Mise au point de la Haute Autorité de Santé sur Mediator", Press Release, (France, 1 December 2010).
12. A. Braillon, The Lancet, 377 (9782), 2003–2004 (2011).
13. EFPIA, "New Study on HTA Processes Highlights Areas for Improvement to Accelerate Patients' Access to Innovative Medicines",
Press Release (Belgium, 13 July 2011).London, UK
|
